Enliven Therapeutics, Inc. (ELVN)
NASDAQ: ELVN · Real-Time Price · USD
22.26
+0.26 (1.18%)
Feb 5, 2025, 11:57 AM EST - Market open
Enliven Therapeutics Employees
Enliven Therapeutics had 46 employees as of December 31, 2023.
Employees
46
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,852,478
Market Cap
1.09B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 46 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 122,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 89,900 |
| Novartis AG | 75,883 |
| Merck & Co. | 72,000 |
| Novo Nordisk | 64,319 |
ELVN News
- 4 weeks ago - Enliven's Early Data Stands Out From Peers - Seeking Alpha
- 2 months ago - Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update - PRNewsWire
- 3 months ago - Enliven Therapeutics to Present at the Jefferies London Healthcare Conference - PRNewsWire
- 4 months ago - Enliven Therapeutics Announces Positive Data Update from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia - GlobeNewsWire
- 4 months ago - Enliven Therapeutics Announces Details Regarding the Presentation of Updated ELVN-001 Phase 1a Data at the ESH-iCMLf 26th Annual John Goldman Conference on CML - GlobeNewsWire
- 8 months ago - Enliven Therapeutics to Present at Two Upcoming Investor Conferences - GlobeNewsWire
- 9 months ago - Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update - GlobeNewsWire
- 10 months ago - Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia - GlobeNewsWire